/
Cardiovascular
Hypertensive
11
Pipeline Programs↗
14
Active Trials↗
19
Companies Involved↗
Hypertensive is an emerging landscape with 11 programs across 19 companies. The most active players are AstraZeneca, Innovent Biologics (Suzhou) Co. Ltd.. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Hydrochlorothiazide (HCTZ) or Olmesartan
The Louis & Rachel Rudin Foundation
Antihypertensive Medication
University of Alberta
Standard Medical Therapy
Post Graduate Institute of Medical Education and Research, Chandigarh
Beta Blocker
Weill Medical College of Cornell University
Calcium Channel Blocker
Minia University
Phase 1
No programs
Approved
No programs
Analysis
Modality Breakdown
91%
Small molecule
10 of 11 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.
Analysis
Trial Status
177
clinical trials
Completed119 · 67%
Unknown status26 · 15%
Terminated10 · 6%
Withdrawn8 · 5%
Recruiting7 · 4%
Not yet recruiting6 · 3%
Other1 · 1%
Clinical Trials
Trial Activity
177 trials
Cardiometabolic Risk in Pregnancy and Postpartum
Recruiting·—·Preclinical·NCT07420465·200 enrolled
Morning Versus Bedtime Dosing of Antihypertensive Medication
Recruiting·—·Phase 4·NCT05089448·300 enrolled
Short-Term Effects of Antihypertensive Drugs on Postural Balance and Fall Risk
Recruiting·—·N/A·NCT07099677·186 enrolled
Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
Recruiting·—·N/A·NCT05498675·180 enrolled
Antihypertensive Drug Selection Based on Hemodynamic Phenotypes
Not yet recruiting·TThe Third Xiangya Hospital of Central South University·Phase 4·NCT07240909·240 enrolled
Immediate Fracture Risk After Antihypertensive Drug Initiation
Not yet recruiting·—·N/A·NCT06964217·10,000,000 enrolled
Cost-Effectiveness of an mHealth Application in Pregnancy Care: A Randomized Multi-Center Study Comparing Penelope Users and Non-Users
Completed·—·Preclinical·NCT07621133·166 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)